EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

QiShenYiQi pill inhibits atherosclerosis by promoting TTC39B-LXR mediated reverse cholesterol transport in liver

Tao-Tao Wang, Cheng-Yong Yang, Li Peng, Li Li, Nan-Ting Chen, Xue Feng, Jing Xie, Ting-Chun Wu, Tao Xu, Yun-Zhi Chen

Phytomedicine · 2024

DOI: 10.1016/j.phymed.2023.155192 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Phytomedicine, 2024. Verfasst von Tao-Tao Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School, Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou 550025, China. Hauptthemen laut MEDLINE: Lipoproteins, Atherosclerosis, Azo Compounds, Drugs, Chinese Herbal. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Tetranucleotide repeat domain protein 39B (TTC39B) was found to combine with ubiquitin ligase E3, and promote the ubiquitination modification of liver X receptor (LXR), which led to the inhibition of reverse cholesterol transport and development of atherosclerosis. QiShenYiQi pill (QSYQ) is a modern Chinese patent drug for treating ischemic cardiovascular diseases, the underlying mechanism is found to promote the expression of LXR-α/ ATP-binding cassette transporter G5 (ABCG5) in the liver of atherosclerotic mice. PURPOSE: The aim of this study is to investigate the effect of QSYQ on TTC39B-LXR mediated reverse cholesterol transport in atherosclerotic mice. STUDY DESIGN AND METHODS: Male apolipoprotein E gene knockout mice (7 weeks old) were fed with high-fat diet and treated with low dose of QSYQ (QSYQ-l, 0.3 g/kg·d), high dose of QSYQ (QSYQ-H, 1.2 g/kg·d) and LXR-α agonist (LXR-A, GW3965 10 mg/kg·d) for 8 weeks. C57BL/6 J mice were fed with normal diet and used as negative control. Oil red O staining, HE staining, ELISA, RNA sequencing, western blot, immunohistochemistry, RT-PCR, cell culture and RNA interference were performed to analyze the effect of QSYQ on atherosclerosis. RESULTS: HE staining showed that QSYQ reduced the atherosclerotic lesion significantly when compared to the control group. ELISA measurement showed that QSYQ decreased serum VLDL and increased serum ApoA1. Oil Red O staining showed that QSYQ reduced the lipid content of liver and protect liver function. Comparative transcriptome RNA-sequence of liver showed that DEGs after QSYQ treatment enriched in high-density lipoprotein particle, ubiquitin ligase complex, bile secretion, etc. Immunohistochemical staining and western blot proved that QSYQ increased the protein expression of hepatic SR-B1, LXR-α, LXR-β, CYP7A1 and ABCG5. Targeted inhibiting Ttc39b gene in vitro further established that QSYQ inhibited the gene expression of Ttc39b, increased the protein expression of SR-B1, LXR-α/β, CYP7A1 and ABCG5 in rat hepatocyte. CONCLUSION: Our results demonstrated the new anti-atherosclerotic mechanism of QSYQ by targeting TTC39B-LXR mediated reverse cholesterol transport in liver. QSYQ not only promoted reverse cholesterol transport, but also improved fatty liver and protected liver function.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LipoproteinsAtherosclerosisAzo CompoundsDrugs, Chinese HerbalMaleMiceRatsAnimalsLiver X ReceptorsCholesterolOrphan Nuclear ReceptorsATP Binding Cassette Transporter, Subfamily G, Member 5Mice, Inbred C57BLLiverMice, Knockout

Stichwörter der Autor:innen

AtherosclerosisQSYQReverse cholesterol transportTTC39Bliver X receptor

Substanzen

Liver X Receptorsqishen yiqiLipoproteinsCholesteroloil red OOrphan Nuclear ReceptorsATP Binding Cassette Transporter, Subfamily G, Member 5Azo CompoundsDrugs, Chinese Herbal

Autor:innen und Institutionen

  • Graduate School, Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou 550025, China.
  • Department of Cardiovascular Internal Medicine, Second Hospital, Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou 550001, China. Electronic address: dr_pengli@126.com.
  • Department of Cardiovascular Internal Medicine, Second Hospital, Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou 550001, China.
  • Basic Medical College, Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou 550025, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Wang, T. T., Yang, C. Y., Peng, L., Li, L., Chen, N. T., Feng, X., Xie, J., Wu, T. C., Xu, T., & Chen, Y. Z. (2024). QiShenYiQi pill inhibits atherosclerosis by promoting TTC39B-LXR mediated reverse cholesterol transport in liver. Phytomedicine. https://doi.org/10.1016/j.phymed.2023.155192

Vancouver

Wang TT, Yang CY, Peng L, Li L, Chen NT, Feng X, et al. QiShenYiQi pill inhibits atherosclerosis by promoting TTC39B-LXR mediated reverse cholesterol transport in liver. Phytomedicine. 2024. doi:10.1016/j.phymed.2023.155192

BibTeX
@article{Wang2024,
  author = {Wang, Tao-Tao and Yang, Cheng-Yong and Peng, Li and Li, Li and Chen, Nan-Ting and Feng, Xue and Xie, Jing and Wu, Ting-Chun and Xu, Tao and Chen, Yun-Zhi},
  title = {QiShenYiQi pill inhibits atherosclerosis by promoting TTC39B-LXR mediated reverse cholesterol transport in liver},
  journal = {Phytomedicine},
  year = {2024},
  doi = {10.1016/j.phymed.2023.155192}
}
Kostenlos starten →